Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects
NCT01289782 is registered in ClinicalTrials.gov with Janssen R&D Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects
- Lead sponsor
- Janssen R&D Ireland
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2011
- Completion date
- January 31, 2013
- Enrollment
- 395 (actual)
- Sites
- 62
Conditions
As the registry lists them; a condition with its own page is linked.